Search

Objective: The TURKMI registry is designed to provide insight into the characteristics, management from symptom onset to hospital discharge, and outcome of patients with acute myocardial infarction (MI) in Turkey. We report the baseline and clinical characteristics of the TURKMI population. Methods: The TURKMI study is a nation-wide registry that was conducted in 50 centers capable of percutaneous coronary intervention selected from each EuroStat NUTS region in Turkey according to population sampling weight, prioritized by the number of hospitals in each region. All consecutive patients with acute MI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018 and November 16, 2018. Results: A total of 1930 consecutive patients (mean age, 62.0 +/- 13.2 years; 26.1% female) with a diagnosis of acute MI were prospectively enrolled. More than half of the patients were diagnosed with non-ST elevation MI (61.9%), and 38.1% were diagnosed with ST elevation MI. Coronary angiography was performed in 93.7% and, percutaneous coronary intervention was performed in 73.2% of the study population. Fibrinolytic therapy was administered to 13 patients (0.018%). Aspirin was prescribed in 99.3% of the patients, and 94% were on dual antiplatelet therapy at the time of discharge. Beta blockers were prescribed in 85.0%, anti-lipid drugs in 96.3%, angiotensin converting enzyme inhibitors in 58.4%, and angiotensin receptor blockers in 7.9%. Comparison with European countries revealed that TURKMI patients experienced MI at younger ages compared with patients in France, Switzerland, and the United Kingdom. The most prevalent risk factors in the TURKMI population were hypercholesterolemia (60.2%), hypertension (49.5%), smoking (48.8%), and diabetes (37.9%). Conclusion: The nation-wide TURKMI registry revealed that hypercholesterolemia, hypertension, and smoking were the most prevalent risk factors. TURKMI patients were younger compared with patients in European Countries. The TURKMI registry also confirmed that current treatment guidelines are largely adopted into clinical cardiology practice in Turkey in terms of antiplatelet, anti-ischemic, and anti-lipid therapy., Turkish Society of Cardiology; Astra-Zeneca CompanyAstraZeneca, TURKMI is an investigator-initiated study sponsored by the Turkish Society of Cardiology that receives major funding from Astra-Zeneca Company for this project.

PubMedID: 29481636 Background: We investigated the effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism, i.e. serum levels of fibroblast growth factor 23(FGF23), Klotho, bone alkaline phosphatase (BAP) and sclerostin, in two cohorts with chronic kidney disease (CKD). Methods: In all, 80 vitamin D-deficient children were selected: 40 with mild to moderate CKD from the ERGO study, a randomized trial of ergocalciferol supplementation [estimated glomerular filtration rate (eGFR) 55 mL/min/1.73 m 2 ], and 40 with advanced CKD from the observational Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study (eGFR 24 mL/min/1.73 m 2 ). In each study, vitamin D supplementation was started in 20 children and 20 matched children not receiving vitamin D served as controls. Measures were taken at baseline and after a median period of 8 months. Age- and gender-related standard deviation scores (SDSs) were calculated. Results: Before vitamin D supplementation, children in the ERGO study had normal FGF23 (median 0.31 SDS) and BAP (-0.10 SDS) but decreased Klotho and sclerostin (-0.77 and - 1.04 SDS, respectively), whereas 4C patients had increased FGF23 (3.87 SDS), BAP (0.78 SDS) and sclerostin (0.76 SDS) but normal Klotho (-0.27 SDS) levels. Vitamin D supplementation further increased FGF23 in 4C but not in ERGO patients. Serum Klotho and sclerostin normalized with vitamin D supplementation in ERGO but remained unchanged in 4C patients. BAP levels were unchanged in all patients. In the total cohort, significant effects of vitamin D supplementation were noted for Klotho at eGFR 40-70mL/min/1.73m 2 . Conclusions: Vitamin D supplementation normalized Klotho and sclerostin in children with mild to moderate CKD but further increased FGF23 in advanced CKD. © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. American Society of Pediatric Nephrology: ESPN 2014.3 This work was supported by the European Society for Pediatric Nephrology (reference number ESPN 2014.3), KfH Foundation for Preventive Medicine and ERA-EDTA (to D.H.).

Achieving normal growth is one of the most challenging problems in the management of children with chronic kidney disease (CKD). Treatment with recombinant human growth hormone (GH) promotes longitudinal growth and likely enables children with CKD and short stature to reach normal adult height. Here, members of the European Society for Paediatric Nephrology (ESPN) CKD–Mineral and Bone Disorder (MBD), Dialysis and Transplantation working groups present clinical practice recommendations for the use of GH in children with CKD on dialysis and after renal transplantation. These recommendations have been developed with input from an external advisory group of paediatric endocrinologists, paediatric nephrologists and patient representatives. We recommend that children with stage 3–5 CKD or on dialysis should be candidates for GH therapy if they have persistent growth failure, defined as a height below the third percentile for age and sex and a height velocity below the twenty-fifth percentile, once other potentially treatable risk factors for growth failure have been adequately addressed and provided the child has growth potential. In children who have received a kidney transplant and fulfil the above growth criteria, we recommend initiation of GH therapy 1 year after transplantation if spontaneous catch-up growth does not occur and steroid-free immunosuppression is not a feasible option. GH should be given at dosages of 0.045–0.05 mg/kg per day by daily subcutaneous injections until the patient has reached their final height or until renal transplantation. In addition to providing treatment recommendations, a cost-effectiveness analysis is provided that might help guide decision-making., This Evidence-Based Guideline developed by members of the European Society for Paediatric Nephrology CKD-MBD, Dialysis and Transplantation working groups presents clinical practice recommendations for the use of growth hormone in children with chronic kidney disease on dialysis and after renal transplantation.

Aim: The aim of the present study was to evaluate the associations between infant feeding modalities and metabolic risk factors for urolithiasis in infants. Patients and Methods: A total of 70 infants (

PubMedID: 28873971 In patients with chronic kidney disease (CKD), renal synthesis of active Vitamin D [1, 25-dihydroxyVitamin D (1, 25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active Vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of Vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active Vitamin D analogues in children with CKD-MBD. A core working group (WG) of the European Society for Paediatric Nephrology (ESPN) CKD-MBD and Dialysis WGs has developed recommendations for the use of active Vitamin D therapy in children with CKD and on dialysis. A second document in parallel with this one covers treatment recommendations for native Vitamin D therapy. The WGs have performed an extensive literature review to include systematic reviews and randomized controlled trials in adults and children with CKD and prospective observational studies in children with CKD. The Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system was used to develop and grade the recommendations. In the absence of applicable study data, the opinion of experts from the ESPN CKD-MBD and Dialysis WGs is provided, but clearly GRADE-ed as such and must be carefully considered by the treating physician and adapted to individual patient needs as appropriate. © The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. National Institute for Health Research RS holds a fellowship with the National Institute for Health Research (NIHR). Members of the ESPN CKD-MBD Working Group: Belgium: A. Prytula, Ghent University, Utopaed. France: J. Bachetta., University Children’s Hospital, Lyon. Germany: D. Haffner., Hannover Medical School, Hannover. G. Klaus, University Children’s Hospital, Marburg. Hungary: G. Reusz, Semmelweis University, Budapest. Italy: E. Verrina, G. Gaslini Institute, Genoa. The Netherlands: J. Groothoff, Academic Medical Center, Amsterdam. Spain: M.A. Gamero, Reina Sofía Universitary Hospital, Córdoba. Russia: E. Petrosyan, Russian National Research Medical University, Moscow. Turkey: S. A. Bakkaloglu, Gazi University Hospital, Ankara; I. Dursun, Erciyes University Faculty of Medicine, Kayseri. United Kingdom: R. Shroff, Great Ormond Street Hospital, London. Members of the ESPN Dialysis Working Group: Austria: C. Aufricht, Medical University of Vienna, Vienna. Belgium: J. Vande Walle, University Hospital Ghent, Department of Pediatric Nephrology/Urology, Ghent. Czech Republic: K. Vondrak, University Hospital Motol, Charles University Prague, 2nd Faculty of Medicine, Prague. Finland: T. Holtta, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki. France: B. Ranchin, Centre de Référence des Maladies Rénales Héréditaires, Hospices Civils de Lyon and Université Lyon, Lyon. M. Fischbach, Hautepierre University Hospital, Strasbourg. Germany: Claus Peter Schmitt, University of Heidelberg, Heidelberg. Günter Klaus, University Children’s Hospital, Marburg. Greece: Constantinos J. Stefanidis, A. and P. Kyriakou Childrens Hospital, Athens; N. Printza, Aristotle University of Thessaloniki, Thessaloniki. Italy: Alberto Edefonti, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan; E. Verrina, Giannina Gaslini Children’s Hospital, Dialysis Unit, Genova; E. Vidal, University Hospital of Padova, Padova. Lithuania: A. Jankauskiene, Vilnius

Although it is known that revascularization is useful for the treatment of patients with ischemic mitral regurgitation (MR), the effects of revascularization on MR have not been well examined. In this study, we aimed to show the effect of revascularization strategies on patients with moderate ischemic MR, quantitatively and prospectively. Forty-seven patients with moderate MR (2 to 3 +) who were offered revascularization due to the diagnosis of coronary artery disease were enrolled in the study. Patients were divided into three groups according to their treatment strategies. Patients who underwent percutaneous coronary intervention (PCI) were defined as group 1 (n=18), patients who underwent surgical revascularization (CABG) as group 2 (n=17) and patients who received only medical treatment as group 3 (n=12). Transthoracic echocardiography (TTE) was performed for all patients at the beginning of the study, and after three months. MR grading was performed using semi-quantitative (I-IV) and quantitative (EOA, RV, and RF) methods. Initial MR grading parameters of the three groups were similar. When the initial and the third month MR parameters of patients were compared, there was a significant decrease in group 1 in effective orifice area (EOA) (p=0.002), regurgitant volume (RV) (p=0.005), regurgitant fraction (RF) (p=0.002) and semi-quantitative MR (p=0.002). There was also a significant decrease in group 2 in EOA (p=0.002), RV (p=0.001), RF (p=0.001) and semi-quantitative MR (p=0.005) grades after 3 months. However, mitral regurgitation severity was not changed with medical treatment in group 3. There was no difference between groups when residual MR grades at the third month were compared with each other (p>0.05). Our study showed that percutaneous or surgical revascularization strategies significantly improved MR parameters, on the other hand no improvement was obtained with medical treatment. In spite of the improvement in the severity of MR, there were still significant residual MR after revascularization strategies without valvular intervention. For this reason it can be suggested that revascularization strategies without valvular intervention is effective but not sufficient for the treatment of patients with ischemic MR.

Potassium plays an important role in cell metabolism and membrane excitability and imbalances in its concentration are important because of ensuing life-threatening conditions. Potassium balance may be disturbed by both the neurohormonal mechanisms in cardiovascular diseases and the drugs used in these diseases. In particular, complications such as malignant ventricular arrhythmias and sudden death are of great concern in potassium instability. This article reviews current knowledge on the drugs that affect potassium balance and the relationship between the potassium ion and cardiac diseases.

27th Congress of the European-Society-of-Cardiology -- SEP 03-07, 2005 -- Stockholm, SWEDEN WOS: 000233987103430 … European Soc Cardiol

Slow coronary flow is a very rare finding in normal coronary arteries. Reserve abnormality of the coronary microvasculature and increased activity of adrenergic system are accused for slow flow. We could not find any study investigating the effects of slow coronary flow on heart rate variability(HRV) and repolarisation of the myocardium. Therefore, we decided to make this trial. Twenty-nine patients with slow coronary flow and normal coronary arteries were included in the study. Twenty-two healthy subjects were accepted as control group. In the slow coronary flow group, TIMI frame counts from coronary angiography, QTc dispersion from 12 lead ECG, HRV from 24 hour ambulatory ECG monitoring were determined. In healthy subjects, HRV and QTc were determined by the same methods. Mean SDNN (109±29), pNN50 (11±7) and triangular index (462±119) of the slow coronary flow group were more depressed than the mean SDNN (146±44), pNN50 (20±16) and triangular index (584±142) of the control group (p values were 0.019, 0.037 and 0.008, respectively). There was no direct correlation between TIMI frame count and HRV indices in the slow coronary flow group. As a result, we suggested that HRV and QTc parameters are changed in the coronary slow flow patients in order to support the theory of increased adrenergic activity may be cause of abnormal coronary flow reserve at the microvascular level and slow coronary flow. Decreased HRV and increased heterogenity of repolarisation of myocardium may be cause of sudden cardiac death in some patients. For this purpose, larger and longer follow-up trials must be conducted in this patient group.